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Abstract: Histone deacetylase inhibitors (HDACi) induce apoptosis preferentially in cancer cells
by caspase pathway activation and reactive oxygen species (ROS) accumulation. Suberoylanilide
hydroxamic acid (SAHA), a HDACi, increases apoptosis via altering intracellular oxidative stress
through thioredoxin (TRX) and TRX binding protein-2 (TBP-2). Because ROS accumulation, as well
as the redox status determined by TBP-2 and TRX, are suggested as possible mechanisms for en-
dometriosis, we queried whether SAHA induces apoptosis of human endometrial cells via the
TRX–TBP-2 system in endometriosis. Eutopic endometrium from participants without endometrio-
sis, and ectopic endometrium from patients with endometriosis, was obtained surgically. Human
endometrial stromal cells (HESCs) and Ishikawa cells were treated with SAHA and cell proliferation
was assessed using the CCK-8 assay. Real-time PCR and Western blotting were used to quantify
TRX and TBP-2 mRNA and protein expression. After inducing oxidative stress, SAHA was applied.
Short-interfering TRX (SiTRX) transfection was performed to see the changes after TRX inhibition.
The mRNA and protein expression of TBP-2 was increased with SAHA concentrations in HESCs sig-
nificantly. The mRNA TBP-2 expression was decreased after oxidative stress, upregulated by adding
2.5 µM of SAHA. The TRX/TBP-2 ratio decreased, apoptosis increased significantly, and SiTRX
transfection decreased with SAHA. In conclusion, SAHA induces apoptosis by modulating the
TRX/TBP-2 system, suggesting its potential as a therapeutic agent for endometriosis.
Keywords: apoptosis; endometriosis; oxidative stress; suberoylanilide hydroxamic acid; thioredoxin
1. Introduction
Endometriosis is a gynecological disease that affects women of reproductive age.
Its incidence varies from 2 to 52%, differing among the following groups: a fertile control
group showed a prevalence of about 6% in the 1990s, a chronic pelvic pain group about
15%, and an infertile group about 21% [1]. Recently, the prevalence of endometriosis
was reported to be 25 to 50% in infertile women and 71 to 87% in women with chronic
pelvic pain [2,3]. According to the global data, the prevalence of endometriosis increased
by 6.4% from 1998 to 2013 [4]. The increase in laparoscopic surgery interventions may
have increased the diagnosis of endometriosis. However, considering that endometriosis
diagnosis is delayed by about 7 to 10 years from initial symptom development and the
prevalence is underestimated, the increase in the incidence rate may be a global trend [5,6].
The pathophysiology of endometriosis is not yet fully understood. There are three
leading theories to explain how endometriosis develops. Retrograde menstruation theory,
also known as Sampson’s theory, suggests that the endometrial cell retrogresses through
salpinx and implants into the peritoneal cavity [7]. Coelomic metaplasia theory proposes
that endometriosis arises due to the metaplasia of mesothelial cells on the peritoneum into
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endometrial cells [8]. Embryonic origin theory hypothesizes that the endometrial cells in
the peritoneal cavity were present from the development, and they spread with exposure
to hormones, oxidative stress or other environmental factors [9].
The management of endometriosis at present is not very different from that 30 years
ago. Surgery is the only effective treatment option, which increases fertility and effectively
assists in pelvic pain management. Although medical treatment is emphasized more than
ever in terms of controlling pelvic pain, preserving fertility, and preventing recurrence, there
are no commercialized drugs available other than hormonal treatment. Individualized
treatment for endometriosis is a critical need as research keeps revealing the various
mechanisms, subtypes, and prognoses of endometriosis. Patients who seek to conceive or
suffer from the side effects of hormonal treatment need other options; however, currently,
these are very few.
Histone deacetylase inhibitors (HDACis) were developed as targeted anticancer agents
that selectively affect cancer cells [10]. Suberoylanilide hydroxamic acid (SAHA) is one of
the most studied HDACis; it exerts significant anticancer activity in hematologic malignan-
cies, breast cancer and lung cancer, and is well tolerated by patients, as shown in clinical
trials [11–14]. For ovarian cancer, HDACi showed effectiveness in combination with other
cancer drugs, such as DNA methyltransferases (DNMTs). The combination overcame the
platinum resistance and showed an improved response to immune checkpoint therapy
in a mouse model [15–17]. Histone acetylation is a crucial process in gene transcription,
and the regulation of enzymes that modulate histone acetylation explains the overgrowth
of cells in various tumors. HDACis induce apoptosis preferentially in cancer cells, pos-
sibly via upregulating pro-death genes or downregulating pro-survival genes. In breast
and ovarian cancer, HDACis showed to increase the effectiveness of cisplatin through a
BRCA1-dependent mechanism, which is being studied in various clinical trials for new
target therapies [18]. Moreover, HDACis increase cell death by increasing reactive oxygen
species (ROS) [19], resulting from the regulation of the redox status by thioredoxin-binding
protein (TBP)-2 and thioredoxin (TRX) [20]. The redox status and oxidative stress were
previously reported as potential mechanisms of endometriosis by our group [21], which
suggested the aberrant expression of TRX and TBP-2 in endometrial stromal cells from
women with endometriosis.
Non-hormonal options, such as modulators, which affect angiogenesis, inflamma-
tory pathways, fibrosis, and oxidative stress, and immune-modulators have been sug-
gested as novel drugs for endometriosis treatment. The hypothesis suggesting that the
immunological mechanism involved in the development of endometriosis may initiate
early development, and that hormones contribute to the inflammatory response, is gaining
momentum [22]. Previously, we proposed that oxidative stress may induce the proliferation
of eutopic endometrial stromal cells, suppress apoptosis, and activate innate immunity
to initiate inflammation [23]. In the current study, we focused on HDACis as a potential
modulator to increase apoptosis in endometriotic cells and alter endometrial stromal cells.
We also aimed to examine whether SAHA induces apoptosis specifically in endometrial
stromal cells by changing the redox status via the regulation of TRX and TBP-2. We collected
eutopic and ectopic endometrium. After cell culture, we performed the CCK-8 assay for
cell proliferation, flow cytometry for apoptosis, real-time PCR and western blotting for the
quantification of TRX and TBP-2, and short-interfering RNA transfection for TRX/TBP-2
ratio and apoptosis.
2. Results
2.1. TRX and TBP-2 Changes to SAHA Treatment in HESCs and Ishikawa Cells
SAHA was administered to eutopic and ectopic human endometrial stromal cells
(HESCs) and Ishkawa cells, to examine TRX and TBP expression in mRNA and protein
level in naïve cells. The mRNA expression of TRX was increased in the stromal cells but not
in the Ishikawa cells (Figure 1A). The upregulation of TBP-2 mRNA and protein synthesis
was significant in HESCs, but not in Isihikawa cells (Figure 1B).
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served in the SAHA-treated groups than in the controls. The mRNA expression of TBP-2 
showed a significant decrease after rHMGB-1 treatment in the stromal or epithelial cells 
(Figure 2C). However, after SAHA treatment, the mRNA expression of TBP-2 increased 
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showed a significant decrease (Figure 2D). 
Figure 1. TRX and TBP-2 expression in endometrial cells, before and after treating with SAHA. (A) Relative mRNA levels of
TRX, TBP-2 was presented according to the treatment doses. There was no difference in the mRNA level in Ishikawa cells,
but there was a significant increase in HESCs up to 5 µM of SAHA treatment. (B) Representative immunoblots revealed
increased TRX and TBP-2 in eutopic and ectopic HESCs, by Western blot; β-actin was used as an internal control.
2.2. Changes after SAHA Treatment in the Oxidative Stress-Induced Altered Endometrial Stromal
and Epithelial Cells
After oxidative stress was induced using rHMGB-1, cell proliferation was increased in
three groups (Figure 2A). Concurrently, oxidative stress led to decreased apoptosis signifi-
cantly in three groups, especially in the ectopic HESCs (Figure 2B, Figure S1). However,
SAHA treatment reversed this effect; moreover, higher levels of apoptosis were observed in
the SAHA-treated groups than in the controls. The mRNA expression of TBP-2 showed a
significant decrease after rHMGB-1 treatment in the stromal or epithelial cells (Figure 2C).
However, after SAHA treatment, the mRNA expression of TBP-2 increased significantly
in the three groups. The TRX/ BP-2 ratio was increased in th ectopic HESCs after
rHMGB-1 treatment; however, soon after SAHA treatment, the TRX/TBP-2 ratio showed a
significant decrease (Figu 2D).
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increased in ectopic HESCs after rHMGB-1 treatment only, and then significantly decreased after SAHA treatment. *, p < 
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2.3. SAHA Treatment Inhibits TRX Gene Expression in the Altered Endometrial Cells 
Eutopic and ectopic HESCs, along with Ishikawa cells, were transfected with siRNA 
to inhibit TRX gene expression. TRX mRNA expression was inhibited by over 50% in the 
three cell groups (Figure S2). Along with the control cells, the SAHA-treated cells were 
Figure 2. Endometrial cell proliferation and TRX, TBP-2 expression after SAHA treatment in stress-induced cells. Oxidative
stress was applied using rHMGB-1 10 ng/mL for 24 h. (A) Endometrial cell proliferation was measured after 48 h of
treatment with 2.5 µM SAHA, which revealed slight increases in three types of cells. (B) The proportion of apoptotic cells
was measured using flow cytometry. Apoptosis was decreased after treating with rHMGB-1, but was soon overwhelmed
with SAHA treatment. (C) The relative mRNA expression levels of TBP-2 showed significant reductions after rHMGB-1
treatment compared to the controls. SAHA increased TBP-2 mRNA expression significantly. (D) The TRX/TBP-2 ratio
was increased in ectopic HESCs after rHMGB-1 treatment only, and then significantly decreased after SAHA treatment.
*, p < 0.05 compared to the control; #, p < 0.05 compared to the rHMGB-1-treated cells.
2.3. SAHA Treatment Inhibits TRX Gene Expression in the Altered Endometrial Cells
Eutopic and ectopic HESCs, along with Ishikawa cells, were transfected with siRNA
to inhibit TRX gene expression. TRX mRNA expression was inhibited by over 50% in the
three cell groups (Figure S2). Along with the control cells, the SAHA-treated cells were
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transfected with siNC and siTRX mRNA. Cells with inhibited TRX expression showed
significantly lower TBP-2 expression levels at the mRNA and protein levels compared to
those of siNC after SAHA treatment (Figure 3A,C). The TRX/TBP-2 ratio was increased
after SAHA treatment in the stroma cells but not in the Ishikawa cells (Figure 3B). After the
suppression of the mRNA expression of TRX, the TRX/TBP-2 ratio decreased significantly.
The levels of apoptosis were significantly higher in the eutopic and ectopic HESCs, as well
as in the Ishikawa cells (Figure 3D) with siTRX transfection after SAHA treatment, than in
those with siNC transfection.
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3. Discussion
Endometriosis is one of the diseases for which early diagnosis and treatment are
important because of their complications, such as symptoms and sequelae, if untreated.
Even though it has been studied for more than 160 years, there are still controversies and
questions regarding its diagnosis, pathogenesis, treatment, and prognosis [24]. Surgery is
still the only treatment which improves fertility and reduces chronic pelvic pain. Recently,
the medical treatment recommends preserving the ovarian reserve, but hormonal treatment,
of which many people have a negative view, is the only option. Therefore, a personalized
treatment option for endometriosis is in need.
SAHA is one type of HDACis which is used as a cancer drug for hematologic malig-
nancies, breast cancer, lung cancer, and ovarian cancer [11–14]. HDACi induces apoptosis
in cancer cells by increasing ROS and regulating the redox status by TBP-2 and TRX, which
was also suggested as a potential pathophysiology of endometriosis [21]. It is assumed that
SAHA can also play a role as a treatment option for endometriosis.
In the present study, we observed that SAHA enhanced HESC apoptosis by changing
TBP-2 expression. TBP-2 modulates the intracellular TRX–oxidation system, thus counter-
acting the oxidative stress induced by TRX binding [25]. TRX is a ribonucleotide reductase
that acts as a scavenger of ROS, providing hydrogen molecules to many protein targets [26].
Localized decreased apoptosis in the ectopic endometrium is a unique characteristic of
endometriosis [27]. In previous studies on cancer cells, SAHA suppressed cell proliferation
in multiple myeloma cells (which the authors present as a ”transformed” cell), normal
breast fibroblasts, and lung fibroblast cells [28]. The mechanism underlying the apoptosis
mediated by SAHA was explained by various theories, including increased intracellular
TRX accumulation and upregulated TBP-2 expression [19].
The intracellular TRX–oxidation system modulates the oxidation state of cells so
that the cells may survive or die. TBP-2 is a binding protein of TRX; it is a negative
regulator that inhibits the reducing activity of TRX. In endometriosis, the decrease in
TBP-2 expression was greater in eutopic HESCs from endometriosis patients than in the
controls [21]. Although there were minimal changes in TRX expression, the TRX/TBP-2
ratio was significantly higher in the endometriosis group than in the controls. Considering
the relationship between TRX and TBP-2, the TRX/TBP-2 ratio may reflect the functional
activity of TRX. In our study, SAHA induced a significant increase in the mRNA and protein
expression of TBP-2 in the stromal cells (eutopic and ectopic HESCs) and minimal changes
in the epithelial cells (Ishikawa cells). In the eutopic and ectopic HESCs, TRX expression
was increased after SAHA treatment, which was different from that observed in the
Ishikawa cells. This finding agrees with that of a previous report, which showed that TRX
accumulation increases after SAHA treatment in normal cells [28].
After oxidative stress was induced in the cells, the cell viability increased in the three
groups. TBP-2 expression was previously shown to decrease after rHMGB-1 treatment,
just like TBP-2 expression, in eutopic HESCs from patients with endometriosis [21]. In our
study, after SAHA treatment, we observed a significant decrease in cell viability in the
three groups, along with an increase in apoptosis. The mRNA and protein expression
of TBP-2 was increased markedly. The relative TRX activity, shown by the TRX/TBP-2
ratio, increased after oxidative stress induction, especially in the ectopic HESCs; however,
the TRX/TBP-2 ratio was significantly lower than that before treatment in the three groups.
The advantage that SAHA possesses over other drugs is its cell-specific activity,
according to the cellular redox state. SAHA induces cell apoptosis mainly in transformed
cells, minimally affecting normal cells. Lately, multiple clinical studies regarding the
application of SAHA in various cancer therapies have been conducted [11,29,30]. In cancer
cells, when the TRX gene is suppressed, sensitivity to SAHA increases. Reduced TRX
is probably caused by the downregulation of TBP-2 expression [19]. It is suggested that
decreased TRX may not protect the cell from oxidative stress; thus, cell death increases
owing to the altered TRX-oxidation system. Our results also revealed significantly higher
levels of apoptosis after siTRX transfection than after siNC transfection in the three groups.
Int. J. Mol. Sci. 2021, 22, 1427 7 of 11
Contrary to previous reports, apoptosis was increased not only in the Ishikawa cells
and ectopic HESCs, but also in the eutopic HESCs. The finding may be explained by
the characteristics of the endometrial cell itself. Unlike other organ, endometrial cells
proliferate, and drop out rapidly and actively every month according to the menstrual cycle.
Therefore, there is a fast turnover of these cells—proliferation, apoptosis and withdrawal—
in nature.
Although TBP-2 and TRX expression in the three groups after rHMGB-1 and SAHA
treatment did not show a sequential change in the eutopic and ectopic HESCs and Ishikawa
cells, a consistent TRX/TBP-2 ratio was shown. After SAHA treatment in the oxidative
stress-induced cells, the TRX/TBP-2 ratio decreased significantly, and apoptosis increased
concordantly. When TRX expression was suppressed, apoptosis following SAHA treatment
increased significantly. The findings suggest the possibility of more severe cell alteration
via oxidative stress and increased apoptosis induced by SAHA. The discrepancy may
be attributed to the manner in which SAHA works in cells, involving not only the TRX–
oxidative system but also epigenetic changes. In the ectopic endometrial stromal cells,
SAHA downregulates the G-protein-coupled estrogen receptor [31].
One limitation of our study is that the design was limited to in vitro experiments.
Although the cell culture and molecular examinations may not reflect the characteristics of
endometriosis thoroughly, stromal cells have been used to study its pathophysiology for
years [32,33]. Except for those ones who desire pregnancy, all the patients who provided
the endometriosis samples were given postoperative adjuvant medical treatment: GnRH
agonist or progestin after their diagnosis. However, their long-term follow-up data were
not compiled for research purposes.
Conclusions
Our study suggests SAHA as a potential novel drug for endometriosis treatment, as it
has been used in anticancer therapy trials. Although our study did not successfully show
the different cell responses to SAHA among the eutopic and ectopic HESCs and Ishikawa
cells, the increased levels of apoptosis suggest its significant potential.
4. Materials and Methods
The overall study workflow is summarized in Figure 4. To examine the manner in
which SAHA affects cell apoptosis selectively, eutopic endometrial stromal cells, ectopic
endometrial stromal cells, and endometrial epithelial cells (Ishikawa cell line) were selected.
Cell proliferation was assessed using a CCK-8 proliferation assay kit, and cell viability was
assessed using the MTT assay. The apoptosis of human endometrial stromal cells (HESCs)
was assessed using flow cytometry. Quantitative real-time polymerase chain reaction (qRT-
PCR) and Western blot analyses were used to quantify the mRNA and protein expression
levels of TRX and TBP-2. After inducing oxidative stress by adding rHMGB-1 to the cells,
SAHA treatment was applied, and the subsequent changes in cell proliferation and viability
as well as TRX and TBP-2 expression were examined. After inhibiting TRX via siRNA
transfection, the cell proliferation and apoptosis induced by SAHA were compared.
4.1. Participants
For cell culture, eutopic endometrium specimens were obtained from 10 patients with-
out endometriosis following a hysterectomy of uterine fibroids, and ectopic endometrium
cells were obtained from 10 patients who had undergone ovarian endometrioma enucle-
ation. All participants were of reproductive age and reportedly had regular menstrual
cycles every 28–30 days. None of the participants received any hormonal treatment for
at least 3 months before surgery. The study was approved by the institutional review
board of Severance Hospital, Yonsei University College of Medicine (IRB No. 4-2015-0466;
Approval date: 14 July 2015). All participants who provided endometrial tissue for cell
culture provided written informed consent.
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enucleation. All participants were of reproductive age and reportedly had regular men-
strual cycles every 28–30 days. None of the participants received any hormonal treatment 
for at least 3 months before surgery. The study was approved by the institutional review 
board of Severance Hospital, Yonsei University College of Medicine (IRB No. 4-2015-0466; 
Approval date: 14th July, 2015). All participants who provided endometrial tissue for cell 
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of the hysterectomy process in the operation room. Tissue (1 × 1 cm) from the endometri-
oma was excised right after enucleation. The specimens were transferred into a buffered 
saline solution directly after isolation and immediately sent to the laboratory for analysis. 
HESCs and human endometrial epithelial cells (Ishikawa cell line, Sigma-Aldrich, St. 
Louis, MO, USA) were cultured using the same method, which was previously described 
[23]. Ishikawa cells (1 × 106) and HESCs (5 × 104) were grown in Dulbecco’s modified Ea-
gle’s medium/F12 (DMEM/F12, HyClone, Logan, UT, USA), treated with 10 ng/mL of 
rHMGB-1 diluted in 2 mL of culture medium, and incubated at 37 °C in a 5% CO2 incuba-
tor for 24 h. The HDACi was added at different concentrations 24 h after seeding, and the 
cells were cultured for 48 h. The cells were recovered after trypsinization and washed; 
then, cell proliferation and viability were determined. 
4.3. Drugs and Chemicals 
SAHA (Cayman, Ann Arbor, MI, USA) was chosen as the HDACi, and rHMGB-1 
(Sino, Beijing, China) (10 ng/mL) was used to induce oxidative stress. After determining 
the dosage, 2.5 μM SAHA was added to the culture of stressed cells. 
4.4. Cell Proliferation and Viability, Analysis of Apoptosis 
Endometrial cells were seeded in 6-well tissue culture plates at a density of 1 × 105 
cells/well. The culture medium was changed to DMEM/F12 containing 2% fetal bovine 
serum (FBS; Gibco, Invitrogen) after 24 h of incubation. After changing the media, endo-
metrial cells were treated with SAHA at concentrations of 1.25, 2.5, 5, and 10 μM for 48 h. 
Cells were treated with rHMGB-1 (10 ng/mL) for 24 h; subsequently, 2.5 μM SAHA was 
added for 48 h to compare the differences after inducing oxidative stress. Subsequently, 
100 μL of CCK-8 (Cell Counting Kit-8; Dojindo, Japan) was added to each well, and the 
plates were incubated at 37 °C for 1 h. Supernatants were transferred to 96-well plates 
after incubation, and the OD was measured at 450 nm using a VersaMax microplate reader 
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4.2. Sample Collection and Cell Culture
Endometrial tissue was obtained by curettage from all participants at the beginning
of the hysterectomy process in the operation room. Tissue (1 × 1 cm) from the endometri-
oma was excised right after enucleation. The specimens were transferred into a buffered
saline solution directly after isolation and immediately sent to the laboratory for analysis.
HESCs and human endometrial epithelial cells (Ishikawa cell line, Sigma-Aldrich, St. Louis,
MO, USA) were cultured using the same method, which was previously described [23].
Ishikawa cells (1 × 106) and HESCs (5 × 104) were grown in Dulbecco’s modified Ea-
gle’s medium/F12 (DMEM/F12, HyClone, Logan, UT, USA), treated with 10 ng/mL of
rHMGB-1 diluted in 2 mL of culture medium, and incubated at 37 ◦C in a 5% CO2 incubator
for 24 h. The HDACi was added at different concentrations 24 h after seeding, and the cells
were cultured for 48 h. The cells were recovered after trypsinization and washed; then,
cell proliferation and viability were determined.
4.3. Drugs and Chemicals
SAHA (Cayman, Ann Arbor, MI, USA) was chosen as the HDACi, and rHMGB-1
(Sino, Beijing, China) (10 ng/mL) was used to induce oxidative stress. After determining
the dosage, 2.5 µM SAHA was added to the culture of stressed cells.
4.4 Cell Proliferation and Viability, Analysis of Apoptosis
Endometrial cells were seeded in 6-well tissue culture plates at a density of
1 × 105 cells/well. The culture medium was changed to DMEM/F12 containing 2%
fetal bovine serum (FBS; Gibco, Invitrogen) after 24 h of incubation. After changing the
media, endometrial cells were treated with SAHA at concentrations of 1.25, 2.5, 5, and
10 µM for 48 h. Cells were treated with rHMGB-1 (10 ng/mL) for 24 h; subsequently, 2.5 µM
SAHA was added for 48 h to compare the differences after inducing oxidative stress. Sub-
sequently, 100 µL of CCK-8 (Cell Counting Kit-8; Dojindo, Japan) was added to each well,
and the plates were incubated at 37 ◦C for 1 h. Supernatants were transferred to 96-well
plates after incubation, and the OD was measure at 450 nm using a VersaMax microplate
rea er (Molecular Devices, Sunnyvale, CA, USA) t calculate the cell proliferation rates.
To measure cell viability, we added 100 µL of MTT solution (Sigma, St Louis, MO, USA) to
each well, and the culture plates were incubated at 37 ◦C for 4 h in a 5% CO2 incubator.
Supernatants were harvested for subsequent Western blot analysis. After removing the
medium, 500 µL of dimethyl sulfoxide (DMSO; Sigma) was added to each well, and the
plates were then incubated for 10 min on a shaker. Finally, the OD was measured at 562 nm
using a VersaMax microplate reader. HESCs (2 × 105) and Ishikawa cells (5 × 105) were
seeded in 100 mm culture dishes and incubated for 48 h in DMEM/F12 containing 10%
FBS. The medium was replaced with DMEM/F12 containing 2% FBS, and the cells were
treated with rHMGB-1 and SAHA. The cells were then stained with 5 mL fluorescein isoth-
iocyanate/annexin V and propidium iodide (PI) according to the manufacturer’s protocol.
Apoptotic cells were identified using flow cytometry (FC 500; Beckman Coulter, Fullerton,
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CA, USA), and the data were analyzed using WinMDI v.2.9 software (The Scripps Research
Institute, San Diego, CA, USA).
4.5. RNA Isolation and qRT-PCR
Cell-free total RNA was extracted from cell lysates using an RNeasy mini kit (Qiagen,
Hilden, Germany). cDNA was synthesized from 1 µg total RNA using oligo-dT primers
(Invitrogen). qRT-PCR of TRX and TBP-2 was carried out using ABI StepOnePlus (Applied
Biosystems, Foster City, CA, USA) and SYBR Green RT-PCR Master mix (Toyobo, Osaka,
Japan). The PCR conditions were as follows: 95 ◦C for 10 min; 40 cycles of 95 ◦C for 15 s,
60 ◦C for 1 min, and 95 ◦C for 15 s. The primers used for TRX, TBP-2, and glyceraldehyde
3 phosphate dehydrogenase (GAPDH) were as follows: TRX, 5′-GGT GTG GGC CTT GCA
AAA T-3′ (sense) and 5′-AAT ATC ACG TTG GAA TAC TTT TCA GAG A-3′ (antisense);
TBP-2, 5′-GGG TGA TAG TGG AGG TGT GTG AA-3′ (sense) and 5′-CCG CAA GCC
AGG ATC CTA A-3′ (antisense); and GAPDH, 5′-TCG ACA GTC AGC CGC ATC TTC
TTT-3′ (sense) and 5′-ACC AAA TCC GTT GAC TCC GAC CTT-3′ (antisense). Data were
normalized to the expression of GAPDH, and the PCR products were separated on a 1.5%
agarose gel containing ethidium bromide. The bands were quantified by densitometry
using ImageJ software (National Institutes of Health, USA).
4.6. Western Blotting
Cells were lysed using a radioimmunoprecipitation assay buffer (RIPA buffer; Intron,
iNtRON Biotechnology, Sungnam, Korea) containing a protease inhibitor cocktail (Cell Sig-
naling Technology, Beverly, MA, USA), mixed, and divided into 40 µL aliquots. The lysates
were collected and centrifuged at 13,000 rpm at 4 ◦C for 30 min, and the amount of protein in
the supernatants was quantified using a BCA protein assay kit (Thermo Scientific, Hudson,
NH, USA). Western blot analysis was then performed using the harvested supernatants.
Thirty micrograms of each lysate were boiled in 5× buffer; the supernatants were then
separated using sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE)
(8%) and transferred to polyvinylidene fluoride (PVDF) membranes (Millipore, Eschborn,
Germany). After blocking with BSA at room temperature for 1 h, the membranes were
incubated with specific primary antibodies against TRX (monoclonal anti-rabbit, 1:50,000;
Abcam, Cambridge, MA, USA), TBP-2 (polyclonal anti-rabbit, 0.3 µg/mL, GeneTex, Irvine,
CA, USA), and GAPDH (monoclonal anti-mouse, 0.1 µg/mL, Millipore) overnight at
4 ◦C. The membranes were then incubated with anti-mouse antibodies (IgG, 0.27 µg/mL,
Jackson, West Grove, PA, USA) and anti-rabbit antibodies (IgG, 0.27 µg/mL, Jackson)
conjugated with horseradish peroxidase (HRP) for 1 h at room temperature. Detection
was facilitated by the use of an enhanced chemiluminescence (ECL) solution (Advansta,
San Francisco, CA, USA), and the bands were quantified by densitometry using ImageJ
software.
4.7. Short-Interfering RNA Transfection
TRX short-interfering RNA (siRNA) was purchased from Bioneer Dharmacon (Lafayette,
Colorado, CO, USA). HESCs were transfected with siRNA oligonucleotides using Lipofec-
tamine RNAiMAX (Gibco, Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
recommendations. After 4 h, the cells were washed and incubated overnight in complete
medium with 10 ng/mL rHMGB-1. On the following day, the cells were treated with 2.5 µM
SAHA or vehicle for 48 h. The effect of TRX downregulation was evaluated using RT-PCR
and Western blot analysis; coordinating cell proliferation was assessed.
4.8. Statistical Analysis
All experiments were performed in triplicate. Kruskal–Wallis tests with Dunn’s
procedure for multiple comparisons were performed to determine the significance of the
differences between groups. Statistical analyses were performed using SPSS 22.0 (IBM,
Armonk, NY, USA). p values less than 0.05 were considered statistically significant.
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